As for his brilliance...his career and achievements are clear...
"Prior to joining Peregrine in 2012, Dr. Hutchins served as Vice President, Preclinical Development at Inhibitex Inc, which was acquired by Bristol-Myers Squibb. From 1991 to 2000, Dr. Hutchins held several senior scientist positions in Discovery Research at Burroughs Wellcome and Glaxo Wellcome, with a visiting professor appointment at Rush Medical College. Dr. Hutchins earned a B.S. in Biology from Oral Roberts University, a Ph.D. in Biomedical Sciences from the University of Texas, Health Science Center at the M.D. Anderson Cancer Center and conducted postdoctoral training in the University of Southern California’s Department of Microbiology at the Norris Cancer Center. Dr. Hutchins’ publications and patents span the fields of oncology, infectious disease, osteoarthritis and immunology."
All small biotechs struggle...but most of the real innovation begins in small creative biotechs. Genentech is a good example. Started small but had a highly creative ethos...something that is often missing in larger organizations. If you don't like the risk don't invest in small biotechs! As for me I like the risk/reward ratio.
News 
Market Data 
Discover 
